T elomere shortening has been considered an aging marker since it represents lifetime exposure to oxidative and inflammatory stress, and it has been shown to be negatively correlated with age, smoking, and mortality up to age 75 years. 1 A recent article in the Archives 2 reported that the benefits of leisure activity include an association with longer telomere length in middle-aged subjects, after adjusting for confounding factors such as body mass index, smoking, and socioeconomic status, sending a potentially powerful message that regular exercise has antiaging effects. We report a study in an elderly Chinese population 65 years and older that suggests that by age 70 years, this beneficial effect on telomere length is much attenuated.
Methods. Four thousand men and women 65 years and older living in the community participated in a health survey between 2001 and 2003. Information was collected regarding self-perceived ranking of social status in terms of income, education, and occupation; history of chronic diseases; smoking habit; and physical activity of all types using the Physical Activity Scale for the Elderly. 3 Body mass index was measured. A venous blood specimen was also collected, and leukocyte DNA was extracted for determination of telomere length using quantitative polymerase chain reaction methods 4 2] years, respectively). The association between telomere length and quartiles of physical activity level was examined using analysis of covariance adjusting for age and other potential confounding factors (body mass index, smoking, and self-perceived socioeconomic status). The statistical package used was SAS version 9.1 (SAS Institute Inc, Cary, North Carolina), and the association was also tested for linear trend using the General Linear Model.
Results. Table 1 gives the baseline characteristics of the subjects, including some comorbidities for which associations with telomere length have been observed previously. There was no significant difference in mean telomere length across quartiles of physical activity, adjusting for age and also body mass index, smoking, and selfperceived socioeconomic ranking for all subjects ( Table 2 ). The results remained unchanged when analyzed separately for men and women.
Comment. There are possible factors that may account for the lack of an association in this study. First, by the seventh decade of life, the role of physical activity may not play such a prominent role in telomere attrition since there may have been selection bias in including only elderly people in this study. Second, a different method of telomere measurement was used (quantitative polymerase chain reaction instead of Southern blot method). The comparison of the results from this study with the recent study on leisure activity 2 does not contradict the concept that the underlying mechanism for the association is psychological stress rather than the total amount of is characterized by elevated pulmonary arterial pressure leading to progressive dyspnea, rightsided heart failure, and ultimately death. The goal in treating PAH is to reduce pulmonary vascular resistance and pulmonary artery pressure as well as improve the functional status of the patient. The pathogenic hallmark of PAH is increased pulmonary vascular resistance, a result of vasoconstriction, vascular remodeling (abnormal proliferation of smooth muscle and sometimes other vascular tissue), and in situ thrombosis. An important root cause of this pathologic condition is endothelial dysfunction, ie, the uncoupling of endothelial nitric oxide synthetase (eNOS), which drives the decrease in the production of the endogenous vasodilator nitric oxide along with increases in the production of the reactive oxygen species peroxynitrite and superoxide.
Unfortunately, for many patients the current treatments used for PAH have limited efficacy and may not substantially alter the clinical course of the disease. This is probably, at least in part, because drugs currently approved for PAH (prostacyclins, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors) do not comprehensively address endothelial dysfunction itself but instead endeavor to counterbalance some subset of its downstream effects (ie, decreased prostacyclin production, increased endothelin production, and decreased nitric oxide and cyclic guanosine monophosphate production; Figure 1) . We describe patient with progressive disease who was not responding to maximal conventional therapy and subsequently responded to treatment with cicletanine, an eNOS coupler currently used in Europe for systemic hypertension.
Report of a Case.
A 33-year-old woman with progressive idiopathic PAH was admitted for progressive dyspnea on exertion and right heart failure. One year prior to admission, she was diagnosed as having idiopathic PAH (right ventricular pressure of 80/10 mm Hg) (right ventricular enddiastolic pressure of 33 mm Hg), pulmonary artery pressure of 72/33 mm Hg) (main pulmonary artery pressure of 50 mm Hg), and pulmonary capillary wedge pressure of 8 mm Hg). She initially responded to treatment with intravenous treprostinil and sildenafil citrate, improving from WHO functional class IV to WHO functional class III. On admission, her blood pressure was 92/50 mm Hg; heart rate, 122/min; respiratory rate, 22/min; and oxygen saturation by pulse oximetry, 89% with 5-L/min nasal cannula oxygen. Findings from admission echocardiography and rightheart catheterization confirmed severe PAH and right ventricular dysfunction, with a mean pulmonary artery pressure of 55 mm Hg, right ventricular end-diastolic pressure of 18 mm Hg, and pulmonary capillary wedge pressure of 8 mm Hg (mixed venous oxygen saturation of 57%). On the basis of her symptoms, the patient was categorized as WHO functional class IV. She had been receiving pulmonary vasodilator therapy with high-dose intravenous treprostinil and sitaxentan, in addition to furosemide (80 mg twice daily) and spironolactone (50 mg twice daily). While in the intensive care unit, she began therapy with tadalafil (20 mg 
